Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

The study will include 28 patients with primary CNS DLBCL who are ineligible with autologous hematopoietic stem cell transplantation or whole brain radiation therapy as consolidation therapy. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for a maximum of 12 cycles, withdrew consent, the disease

Trial Details

NCT ID
NCT05260619
Phase
PHASE2
Sponsor
Seoul National University Bundang Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • lenalidomide
Locations (sample)
  • Seongnam-si, Please Select, South Korea|37.43861,127.13778

Key Eligibility Criteria

  • PCNSL patients whose achieved response (CR/PR) after first line immunochemotherapy treatment
  • histology confirmed to be PCNSL
  • Hematology values must be within the following limits:
  • Absolute neutrophil count (ANC) ≥ 1000/µl Platelets ≥75,000/µl

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →